Clinical Trials on Selective Estrogen Receptor Modulator (SERM)

Total 244 results

Toshihiko Kono

Unknown

Comparison Between Raloxifene and Bazedoxifene

Selective Estrogen Receptor Modulator

Japan
Toshihiko Kono

Unknown

The Effects of Seasonal Changes in Osteoporosis Treatment

Selective Estrogen Receptor Modulator (SERM)

Japan
Istituto Scientifico Romagnolo per lo Studio e...

Terminated

A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT) (ARTT)

Estrogen Receptor Positive Breast Cancer | Androgen Receptor Gene Overexpression | Progesterone Receptor Positive Tumor | Metastatic Breastcancer | Estrogen Receptor Negative Neoplasm | Progesterone Receptor Negative Neoplasm

Italy
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Genentech, Inc.; Translational Breast Cancer... and other collaborators

Terminated

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

Stage IV Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast Carcinoma

United States
AC Camargo Cancer Center
H. Lee Moffitt Cancer Center and Research Institute

Completed

Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression (HORMONET)

Neuroendocrine Tumors | Estrogen Receptor Positive Tumor | Progesterone Receptor Positive Tumor

United States, Brazil
City of Hope Medical Center
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Stage IV Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive

United States
Syndax Pharmaceuticals

Completed

Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer (ENCORE301)

Breast Cancer | ER+ Breast Cancer | Estrogen Receptor-Positive Breast Cancer | Breast Cancer, Estrogen Receptor-Positive

United States, Czechia, Canada, Hungary, Russian Federation
Eisai Inc.

Completed

Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer

Breast Cancer | Breast Neoplasms | Cancer, Breast | Breast Cancer Female | Estrogen Receptor Positive Tumor | Breast Adenocarcinoma | ER Positive | Estrogen-receptor Positive Breast Cancer

France, United Kingdom, United States
University of Washington
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery

HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...

United States
Northwestern University
National Cancer Institute (NCI); MedImmune LLC; Avon Breast Cancer Foundation

Completed

MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Terminated

Evaluation of Mammographic Breast Density in Participants With Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502

Breast Carcinoma | Estrogen Receptor Negative | Progesterone Receptor Negative

United States, Guam
National Cancer Institute (NCI)

Completed

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive | Stage IIIC Breast Cancer AJCC v6 | Stage IV Breast Cancer AJCC v6 and v7

United States, Puerto Rico
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

Inflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast Cancer

United States
Vanderbilt University Medical Center

Completed

Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension (T3PAH)

Lung Diseases | Hypertension | Pulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Primary Pulmonary Hypertension | Estrogens | Tamoxifen | Estrogen Receptor Antagonist | Hormone Antagonists

United States
National Cancer Institute (NCI)

Terminated

MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive and other conditions

United States
University Medical Center Groningen

Terminated

Validation of [18F]FES for Imaging of Brain Estrogen Receptors

Postmenopausal | Psychiatric/Mood Disorder | Patient | Estrogen Receptor Levels | Premenopausal

Netherlands
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer

Invasive Breast Carcinoma | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive

United States
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma

United States
Andrei Iagaru
General Electric

Completed

68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer

Breast Carcinoma | Estrogen Receptor Positive

United States
Virginia Commonwealth University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Active, not recruiting

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IIA Breast Cancer | Stage IIB Breast Cancer | HER2/Neu Negative | Progesterone Receptor Negative | Estrogen Receptor-positive Breast Cancer | Breast Adenocarcinoma | Progesterone Receptor Positive... and other conditions

United States
University Hospital, Tours
Institut Cancerologie de l'Ouest

Terminated

A Randomised Study of Docosahexaenoic Acid (DHA) in Metastatic Breast Cancer (DHALYA)

Metastatic Breast Cancer | Estrogen Receptor Positive Tumor | Progesterone Receptor Positive Tumor | HER-2 Negative Tumor

France
Polly A. Niravath, MD

Recruiting

REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy (REVIVE)

Breast Cancer | Estrogen Receptor Positive Breast Cancer

United States
University of Pittsburgh Medical Center

Completed

Electronic Medical Record-Based Nudge to Reduce SLNB

Breast Cancer | Estrogen-receptor-positive Breast Cancer

United States
Queen Mary University of London
Hoffmann-La Roche; Asan Medical Center; Kliniken Essen-Mitte; MedSIR

Active, not recruiting

Pre-operative Immunotherapy Combination Strategies in Breast Cancer (ECLIPSE)

Breast Cancer | Estrogen Receptor-positive Breast Cancer

United Kingdom
Velindre NHS Trust
AstraZeneca; Cardiff and Vale University Health Board; Covance; Cenduit LLC

Active, not recruiting

Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer (FAKTION)

Estrogen Receptor Positive Breast Cancer

United Kingdom
University of Virginia

Withdrawn

COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer (Breast 51)

Breast Cancer | Estrogen Receptor-positive Breast Cancer

United States
The Methodist Hospital Research Institute
Millennium Pharmaceuticals, Inc.

Completed

TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer (ANETT)

Estrogen Receptor Positive Breast Cancer

United States
Queen Mary University of London
AstraZeneca

Unknown

A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer (MANTA)

Estrogen Receptor Positive Breast Cancer

Spain, United Kingdom, France, Portugal, Georgia, Korea, Republic of, Germany, Hungary, Romania
AHS Cancer Control Alberta

Active, not recruiting

A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers (PRESTO)

Estrogen Receptor Positive Breast Cancer

Canada
Western Regional Medical Center

Terminated

Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy (ABC01)

Estrogen Receptor Positive Breast Cancer

United States
Eisai Inc.

Completed

Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

Breast Cancer | Estrogen Receptor Positive Tumor

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

HER2/Neu Negative | Stage IV Breast Cancer AJCC v6 and v7 | Estrogen Receptor and/or Progesterone Receptor Positive

United States
National Cancer Institute (NCI)

Completed

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Adult Solid Neoplasm

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer

Stage IV Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Triple-negative Breast Carcinoma | Progesterone Receptor-negative

United States
Oana Danciu, MD
Pfizer; Big Ten Cancer Research Consortium

Active, not recruiting

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

Metastatic Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Estrogen Receptor Positive Breast Cancer | Progesterone Receptor Positive Tumor

United States
National Cancer Institute (NCI)

Completed

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIB Breast... and other conditions

United States
National Cancer Institute (NCI)

Completed

F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast Cancer

United States
University of Utah

Recruiting

[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial

Estrogen Receptor Positive Breast Cancer

United States
Vanderbilt-Ingram Cancer Center

Active, not recruiting

A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer

Estrogen Receptor-positive Breast Cancer

United States
National Cancer Institute (NCI)

Withdrawn

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7
Instituto Valenciano de Infertilidad, IVI VALENCIA

Completed

Methods for Objective Selection of Competent Sperm (MACS)

Sperm Selection

Spain
UNICANCER
Breast International Group

Completed

Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure (ULTIMATE)

Breast Cancer | Menopause | Estrogen Receptor Positive Tumor | Hormone Antagonist

France, Sweden, Spain
University of Nebraska
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone... and other conditions

United States
Université de Sherbrooke

Completed

Immediate Skin-to-skin Contact After C-section (CALIN)

Elective Cesarean Section | Term Birth (Pregnancy)

Canada
Indiana University
Translational Breast Cancer Research Consortium

Completed

Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer

United States
National Cancer Institute (NCI)

Terminated

RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Metastatic Triple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Androgen Receptor Positive

United States
Duke University
United States Department of Defense

Completed

Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast Cancer

Healthy | Breast Cancer | Estrogen Receptor-positive Breast Cancer

United States
First Affiliated Hospital Xi'an Jiaotong University

Unknown

The Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast Cancer (PET)

Estrogen Receptor-positive Breast Cancer | Fulvestrant

China

Clinical Trials on Selective Estrogen Receptor Modulator (SERM)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations